FIELD: medicine.
SUBSTANCE: group of inventions relates to pharmaceutical water-based composition, containing 300 U/ml [equimolar to 300 IU of human insulin] of insulin glargine for treatment of type 1 and 2 diabetes.
EFFECT: application of claimed inventions makes it possible to provide basal insulin supply for 24 hours after subcutaneous injection of a single dose.
9 dwg, 12 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS OF LONG-TERM ACTION INSULINS | 2015 |
|
RU2642662C2 |
| TREATING DIABETES MELLITUS WITH LONG-ACTING INSULIN FORMULATIONS | 2014 |
|
RU2705797C2 |
| COMBINATION OF INSULIN AND GLP-1 AGONIST | 2014 |
|
RU2682671C2 |
| COMBINATION OF INSULIN AND GLP-1 AGONIST | 2009 |
|
RU2532378C2 |
| TREATING DIABETES MELLITUS BY INSULIN INJECTIONS AS LITTLE AS ONCE DAY | 2009 |
|
RU2540922C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AGONIST GLP-1, INSULIN AND METHIONINE | 2010 |
|
RU2537239C2 |
| STABLE COMPOSITION OF INSULIN GLULISIN | 2014 |
|
RU2691059C2 |
| PHARMACEUTICAL COMPOSITION | 2013 |
|
RU2670106C2 |
| INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION | 2014 |
|
RU2684398C2 |
| APPLICATION OF SUPERFAST-ACTING INSULIN | 2009 |
|
RU2519706C2 |
